Anthem Biosciences Limited IPO: Issue Price, Listing Gain and Share Price Now
Anthem Biosciences Limited listed on 21-Jul-2025 at ₹730.35 against an issue price of ₹570 , a listing gain of +28.13%. It last traded at ₹874.6. This page is the record of that issue and what has happened to it since — reported figures only.
Anthem Biosciences Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹570 |
| Listing price (listing-day close) | ₹730.35 |
| Listing gain | +28.13% |
| Price now | ₹874.6 |
| Change from issue price | +53.44% |
| Change from listing-day close | +19.75% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Anthem Biosciences Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹570 |
| Issue size | ₹3,395 Cr |
| Offer for sale | ₹3,395 Cr |
| Issue opened | 14-Jul-2025 |
| Issue closed | 16-Jul-2025 |
| Listed on | 21-Jul-2025 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | JM Financial (left lead) |
How the Anthem Biosciences Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 192.80x |
| NII | 44.70x |
| Retail | 5.98x |
| Total | 67.42x |
Anthem Biosciences Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹49,262 Cr |
| Trailing P/E | 83.00x |
| Return on capital employed | 30.4% |
| Return on equity | 22.3% |
| 52-week high | ₹904 |
| 52-week low | ₹579 |
| Sector | Biotechnology |
Fundamentals are as of the desk's last harvest and move with the market.
- Anthem Biosciences Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.